Intravenous Versus Perineural Ondansetron for Laparoscopic Sleeve Gastrectomy
Intravenous Versus Perineural Ondansetron as an Adjuvant in Autonomic Neural Blockade for Laparoscopic Sleeve Gastrectomy: A Two-Center, Randomized, Double-Blind, Non-inferiority Trial
Tanta University
170 participants
Feb 16, 2025
INTERVENTIONAL
Conditions
Summary
This prospective randomized non-inferiority study will be conducted to compare the analgesic anti-emetic effects of intravenous ondansetron versus perineural ondansetron in patients undergoing laparoscopic sleeve gastrectomy.
Eligibility
Inclusion Criteria4
- Patients of either sex
- American Society Anesthesiologists physical (ASA) status II-III
- age between 18-65 years old
- Body mass index (BMI) \>35 kg/m2 with comorbidity or \> 40 kg/m2 -- undergoing laparoscopic sleeve gastrectomy with intraoperative surgeon performed laparoscopic paragastric autonomic neural blockade..
Exclusion Criteria8
- Allergy to experimental drugs.
- Known to have long QT, previous history of postoperative nausea and vomiting
- Abuse of alcohol, analgesia, or sedative antidepressant drugs
- Chronic pain disorders
- History of previous upper gastrointestinal system surgery, those with surgery-related complications during or after surgery.
- Liver or kidney failure
- Performance of concomitant procedures in addition to laparoscopic sleeve gastrectomy
- Anesthetic complications that may alter the postoperative management protocol.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Para-gastric autonomic neural blockade will be performed (after separation of the stomach and performing the methylene blue leak test) using 20 ml solution containing 18 ml bupivacaine 0.5% plus 2 ml (4 mg) ondansetron. At the same time, 15 ml saline will be injected slowly IV over 15 minutes.
Para-gastric autonomic neural blockade will be performed (after separation of the stomach and performing the methylene blue leak test) using 20 ml solution containing 18 ml bupivacaine 0.5% plus 2 ml saline. At the same time, 4 mg (2 ml) ondansetron mixed with 13 ml saline (total 15 ml) will be slowly injected IV over 15 minutes.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06810882